Ethics and Research with Pregnant Women: Lessons from HIV/AIDS
HIV/AIDS is among the most serious diseases confronting women who are pregnant. It is also one of the few areas of research involving humans where there is a long track record of research involving pregnant women. Yet the HIV/AIDS research community has struggled to expand the research agenda from research to prevent mother-to-child transmission of HIV to research encompassing issues pertaining to the pregnant woman’s own health. Research questions of interest include: which antiretrovirals are safest and most effective for pregnant women; how best to pursue preventive regimes for pregnant women who are not infected; or, how to treat HIV’s deadly co-infections, such as tuberculosis (TB), during pregnancy. In this chapter, we describe two key lessons about research in pregnancy from the context of HIV/AIDS: first, why addressing the health needs of pregnant women, not just the needs of their offspring, is so critical; and second, why doing so is immediately possible, even as we work to resolve certain ethical and regulatory debates, particularly about when it is appropriate to impose foetal risk without the prospect of foetal benefit. In particular, the HIV/AIDS context shows how treatment or prevention of maternal disease often entails not just risk – but the prospect of benefit – to the foetus; and creative trial designs can advance no-benefit studies without imposing foetal risk in the first place. For all the challenges that research with pregnant women entails, the HIV/AIDS context reveals that it is possible to conduct a wide range of important research during pregnancy that is both ethically responsible and consonant with US regulations.
KeywordsPregnant women Clinical research Research ethics Pregnancy HIV/AIDS Women’s health Clinical trials
- AIDSInfo. 2014. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. Accessed 8 Apr 2016.
- Allen, V.M., and B.A. Armson for the SOGC Genetics Committee. 2007. SOGC clinical practice guideline – Teratology associated with pre-existing and gestational diabetes. Journal of Obstetrics and Gynaecology Canada 29(11): 927–944.Google Scholar
- Andrew, M.A., M.R. Easterling, D.B. Carr, D. Shen, D.L. Buchanan, T. Rutherford, et al. 2007. Amoxicillin pharmacokinetics in pregnant women: Modeling and simulations of dosage strategies. Clinical Pharmacology and Therapeutics 81(4): 547–556.Google Scholar
- Ashcroft, R. 2016. Ethical issues in a trial of maternal gene transfer to improve foetal growth. In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 247–263. Cham: Springer.Google Scholar
- AVERT. 2014. Funding for HIV and AIDS. http://www.avert.org/funding-hiv-and-aids.htm. Accessed 8 Apr 2016.
- Baeten, J.M., D. Donnell, P. Ndase, N.R. Mugo, J.D. Campbell, J. Wangisi et al. 2012. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England Journal of Medicine 367(5): 399–410.Google Scholar
- Ballantyne, A., and W. Rogers. 2016. Pregnancy, vulnerability, and the risk of exploitation in clinical research. In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 139–159. Cham: Springer.Google Scholar
- Birkhead, G.S., W.P. Pulver, B.L. Warren, S. Hackel, D. Rodríguez, and L. Smith 2010. Acquiring human immunodeficiency virus during pregnancy and mother-to-child transmission in New York. Obstetrics and Gynecology 115(6): 1247–1255.Google Scholar
- Blonk, M., A. Colbers, C. Hidalgo-Tenorio, K. Kabeya, K. Weizsäcker, A. Haberl, et al. 2015. Raltegravir in HIV-1 infected pregnant women: Pharmacokinetics, safety and efficacy. Clinical Infectious Diseases 61(5): 809–816.Google Scholar
- CDC (Centers for Disease Control). 2014. HIV in pregnant women, infants and children. http://www.cdc.gov/hiv/risk/gender/pregnantwomen/facts/index.html. Accessed 8 Apr 2016.
- Chi, B.H., M.R. Adler, O. Bolu, D. Mbori-Ngacha, D. K. Ekouevi, A. Gieselman, et al. 2012. Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President’s Emergency Plan for AIDS Relief. JAIDS 15(60, Suppl 3): S78–S87.Google Scholar
- DHHS (US Department of Health and Human Services). 2009. Code of Federal Regulations: Title 45, Part 46, Protection of Human Subjects. http://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html. Accessed 3 Oct 2016.
- Dinh, T., K.P. Delaney, A. Goga, D. Jackson, C. Lombard, S. Woldesenbet, et al. 2015. Impact of maternal HIV seroconversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4–8 weeks postpartum in South Africa 2011–2012: A national population-based evaluation. PLoS ONE 10(5): e0125525.CrossRefPubMedPubMedCentralGoogle Scholar
- Ekouevi, D.K., P.A. Coffie, E. Ouattara, R. Moh, C. Amani-Bosse, E. Mossou, et al. 2011. Pregnancy outcomes in women exposed to efavirenz and nevirapine: An appraisal of the IeDEA West Africa and ANRS databases, Abidjan, Côte d’Ivoire. JAIDS 56(2): 183–187.Google Scholar
- Ells, C., and C. Lyster. 2016. Research ethics review of drug trials targeting medical conditions of pregnant women. In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 95–118. Cham: Springer.Google Scholar
- EWG (Environmental Working Group). 2005. Body burden: The pollution in newborns. A benchmark investigation of industrial chemicals, pollutants, and pesticides in umbilical cord blood. http://www.ewg.org/research/body-burden-pollution-newborns. Accessed 8 Apr 2016.
- Gupta, A., J.S. Matthad, S.M. Abdel-Rahman, J.D. Albano, R. Botgros, V. Brown, et al. 2016. Toward earlier inclusion of pregnant and postpartum women in tuberculosis drug trials: Consensus statements from an international expert panel. TB drug trials: Consensus statements from an expert panel. Clinical Infectious Diseases 62(6): 761–769.CrossRefPubMedGoogle Scholar
- Healy, D., and D. Mangin. 2016. Does my bias look big in this? In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 197–208. Cham: Springer.Google Scholar
- HIV Prevention Trials Network. 2006. HPTN 035: Phase II/IIb safety and effectiveness study of the vaginal microbicides buffergel and 0.5 % pro 2000/5 gel (p) for the prevention of HIV infection in women. http://www.hptn.org/research_studies/hptn035.asp. Accessed 8 Apr 2016.
- Johnson, L.S.M. 2016. When hypothetical vulnerability becomes actual: Research participation and the autonomy of pregnant women. In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 161–178. Cham: Springer.Google Scholar
- Kelland, K. 2010. UNICEF says HIV-free generation is achievable. Reuters Health (London), 30 November. http://www.reuters.com/article/2010/11/30/us-aids-unicef-idUSTRE6AT3IC20101130. Accessed 8 Apr 2016.
- Kukla, R. 2016. Equipoise, uncertainty, and inductive risk in research involving pregnant women. In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 179–196. Cham: Springer.Google Scholar
- Maternal Fetal Medicine Units Network. 2015. Research projects. https://mfmu.bsc.gwu.edu/research-projects. Accessed 8 Apr 2016.
- Merton, V. 1996. Ethical obstacles to women in biomedical research. In Feminism and bioethics: Beyond reproduction, ed. S. Wolf, 216–251. Oxford/New York: Oxford University Press.Google Scholar
- Microbicide Trials Network. 2008. MTN-003: Phase 2B safety and effectiveness study of tenofovir 1 % gel, tenofovir disoproxil fumarate tablet and emtricitabine/tenofovir disoproxil fumarate tablet for the prevention of HIV infection in women. http://www.mtnstopshiv.org/sites/default/files/attachments/MTN-003_FINAL_Version_2.0_31DEC2010.pdf. Accessed 8 Apr 2016.
- PhRMA – America’s Biopharmaceutical Research Companies. 2014. 2014 report – Medicines in development: HIV/AIDS. http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-hiv-aids.pdf. Accessed 8 Apr 2016.
- Presidential Commission for the Study of Bioethical Issues. 2011. “Ethically impossible”: STD research in Guatamala from 1946 to 1948. http://bioethics.gov/sites/default/files/Ethically-Impossible_PCSBI.pdf. Accessed 8 Apr 2016.
- Spencer, B. 2015. Taking antidepressants during pregnancy increases risk of baby developing a rare circulation problem which causes permanent disabilities. Daily Mail, 2 June. http://www.dailymail.co.uk/health/article-3107709/Taking-antidepressants-pregnancy-increases-risk-baby-developing-rare-circulation-problem-causes-permanent-disabilities.html. Accessed 8 Apr 2016.
- UNAIDS. 2014. 2014 progress report on the global plan. http://www.unaids.org/sites/default/files/documents/JC2681_2014-Global-Plan-progress_en.pdf. Accessed 8 Apr 2016.
- WHO (World Health Organization). 2014. Global guidance on criteria and processes for validation: Elimination of maternal to child transmission (EMTCT) of HIV and syphilis. http://apps.who.int/iris/bitstream/10665/112858/1/9789241505888_eng.pdf?ua=1&ua=1. Accessed 8 Apr 2016.
- WHO (World Health Organization). 2015. Mother to child transmission of HIV. http://www.who.int/hiv/topics/mtct/en/. Accessed 8 Apr 2016.
- Wild, V., and N. Biller-Andorno. 2016. Pregnant women’s views about participation in clinical research. In Clinical research involving pregnant women, eds. F. Baylis and A. Ballantyne, 119–136. Cham: Springer.Google Scholar
- Yeh, R.F., N.L. Rezk, A.D. Kashuba, J.B. Dumond, H.L. Tappouni, H.C. Tien, et al. 2009. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrobial Agents and Chemotherapy 53(6): 2367–2374.CrossRefPubMedPubMedCentralGoogle Scholar